- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04905069
Efficacité du système SpaceOAR Vue chez les sujets atteints d'un cancer de la prostate traités par radiothérapie corporelle stéréotaxique (SABRE)
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is designed to evaluate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in participants undergoing Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Bonn, Allemagne, D-53129
- MEDICLIN Robert Janker Klinik
-
Nuremberg, Allemagne, 90419
- Klinikum Nurnberg Nord
-
-
-
-
New South Wales
-
Waratah, New South Wales, Australie, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Woolloongabba, Queensland, Australie, 4102
- Princess Alexandra Hospital - ROPAIR
-
-
Western Australia
-
Nedlands, Western Australia, Australie, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Barakaldo, Espagne, 48903
- Hospital Universitario Cruces
-
Madrid, Espagne, 28002
- GenesisCare, Hospital San Francisco de Asis
-
Madrid, Espagne
- Hospital Universitario Ramón y Cajal
-
-
-
-
-
Levallois-Perret, France, 92300
- Institut de Radiothérapie & Radiochirurgie HARTMANN
-
-
Cedex
-
Villejuif, Cedex, France, 94805
- Institut Gustave Roussy
-
-
-
-
-
Cork, Irlande, T12 DV56
- Bon Secours Radiotherapy Cork
-
-
-
-
-
Parma, Italie, 43126
- Azienda Ospedaliero Universitaria di Parma
-
Rome, Italie
- Policlinico Universitario Agostino Gemelli
-
Verona, Italie, 37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Belfast, Royaume-Uni, BT9 7AB
- Belfast City Hospital
-
Bristol, Royaume-Uni, BS2 8ED
- Bristol Haematology and Oncology Centre
-
London, Royaume-Uni, SW3 6JJ
- Royal Marsden Hospital
-
Norwich, Royaume-Uni, NR4 7UY
- Norfolk and Norwich University Hospital NHS Trust
-
Plymouth, Royaume-Uni, PL6 8DH
- Derriford General Hospital
-
-
Surrey
-
Guildford, Surrey, Royaume-Uni, GU27XX
- Royal Surrey County Hospital NHS Foundation Trust
-
-
Wales
-
Cardiff, Wales, Royaume-Uni, CF14 2TL
- Velindre Cancer Centre
-
-
-
-
-
Basel, Suisse, CH-4031
- University Hospital Basel
-
Bern, Suisse, 3010
- Inselspital - University Hospital Bern
-
-
-
-
Florida
-
Fort Myers, Florida, États-Unis, 33908
- GenesisCare USA
-
Tampa, Florida, États-Unis, 33609
- Florida Urology Partners, LLC
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Kansas University Medical Center
-
-
Michigan
-
Troy, Michigan, États-Unis, 48098
- GenesisCare USA
-
-
New Jersey
-
Bloomfield, New Jersey, États-Unis, 07003
- New Jersey Urology, a Summit Health Company
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, États-Unis, 29572
- Dr. John Sylvester
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years old.
- Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
- Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
- Clinical Stage T2b - T2c (AJCC 6th edition) tumor
- Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.
Exclusion Criteria:
- Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
- Clinical stage T3 or T4 (AJCC 6th edition) tumor
- Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
- Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
- Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
- Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
- Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
- History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
- History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
- History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
- History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
- Bleeding hemorrhoids requiring medical intervention within the prior three months.
- Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
- Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
- Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
- If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
- Unable to comply with the study requirements or follow-up schedule.
- Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
- Known iodine sensitivity or allergy
- Known polyethylene glycol (PEG) sensitivity or allergy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: No-Spacer Control
Subjects will receive radiotherapy without the use of the SpaceOAR Vue. |
|
|
Expérimental: SpaceOAR Vue
Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel. |
The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Late Gastrointestinal (GI) Toxicity
Délai: 3 to 24 months post-SBRT initiation
|
Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation |
3 to 24 months post-SBRT initiation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EPIC-26 bowel score
Délai: 24 months post-SBRT initiation
|
Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation. |
24 months post-SBRT initiation
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Suneil Jain, MB, BCh, PhD, Queen's University, Belfast
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- U0702
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .